Member Info for TRENCH123

KingH, thanks for taking the time to present your detailed analysis. Exciting times ahead

Jaari, you have lost serious money on PYC in the past and are very bitter about it. Thanks for letting us know, now move on

Laura, this is where I feel a decent re-rate will come from. The partnership will likely open up some great opportunities for PYC in the US market

It is good news that PYC are renewing contracts, the more the better. Each one contributes towards overheads and a move nearer to being profitable

Commercial deals will come from the dosing tools and sustain a decent recurring income. Until such time, volume is the key here. We are seeing real progress this calendar year in attracting new business and also repeat business with existing clients

Jaari, try to do a little more research before you slag-off PYC

Bicycle share price is currently $7.56 down from a high of $28.67 in the last 12 months. Not too great for their shareholders at the moment, contrary to your comments

Fair point, but It encouraged me to invest £1700 and pleased to do so

Stockraiser I agree with your sentiment 'All the recent positive news will eventually have to be accepted by the market and a re-rate will naturally occur. Could be today, but the longer it takes the bigger the re-rate'

For those who take a serious interest in the future of the company and are not willing it to fail :-

The company are working on multiple contracts at any one time and this additional revenue can only be seen as a positive IMHO

Jaari, you must be posting on the wrong company

Avocet, sorry to disappoint you but the price has been very stable here for the past three weeks

You give me the impression, maybe wrongly, that you have some form of OCD. Please prove me wrong by concentrating your future comments (good or bad) about PYC, as opposed to posting irrelevant twaddle based on personal vendettas

Interesting incidental comment in the text 'Although the team’s partnerships with other Milton Park occupiers remains confidential ....'

Two companies which operate from Milton Park and where some form of 'partnership' could be in place are Exscientia (who work with PYC client Merck KgaA) and S-Cubed Biometrics - PYC are actively looking to establish their biometrics offering

Https://www.miltonpark.co.uk/business/company-spotlight-physiomics/

If the collaboration goes well then we could potentially see Doseme (which is privately owned) making a move for PYC

The PYC announcement earlier this month referred to a 'non-binding Heads of Terms with the intention of expanding their partnership (with Doseme) beyond the Company's current personalised dosing software'. It further mentions 'The two parties are actively working to identify potential projects .... and further announcements on this will be made when appropriate'

The announcement was not unexpected as part of the February funding was earmarked to 'Explore a deeper relationship with DoseMe to develop models to be implemented on their platform' however the extent of the collaboration is potentially much more extensive than could have been anticipated

I fully expect an announcement to be made by over the next couple of months setting out some initial projects, Could be interesting

It would appear that most of today's sales were from purchases made yesterday.

Your highlighting of the MSA is a very valid one. I too think the MSA could be significant

There is increasing demand for PYC's expertise. The number of recent contract announcements, the increasing forward booking of work and the initiation of a Master Service Agreement with a new client are clear indicators of this

Following a busy first 6 months, we are excited to keep up momentum for the rest of 2025 and look forward to attending some key industry events to discuss the future of drug development and share updates on our services to support data-driven decisions for our clients.

We’re kicking things off in Birmingham this September for the first UK Mathematical Biology Conference, supported by the Heilbronn Institute for Mathematical Research (HIMR) and the UKRI EPSRC. A great chance to discuss the latest advancements in modelling techniques and how they can be applied to accelerate drug development.

In October, we’ll be heading to Colorado for the ACoP Annual Conference, hosted by the International Society of Pharmacometrics – joining industry leaders to explore how PKPD, PBPK, and QSP modelling can support key decisions across the development process.

In November, we’re excited to return to #BIOEurope in Vienna and look forward to connecting with pharma and biotech leaders to discuss the latest industry trends. We’ll also be at PKUK at the University of Warwick – a key event for experts in PK/PD and quantitative pharmacology.

PYC have announced four new events on twitter, including US and Austria

Agree Laura, very impressive

I think something was mentioned about an interim progress report on the joint project, so yes I would be expecting an update before long. Having said that it only six months before the PREDICT-ONC trial completes, so not long to wait anyway